MedPath

Treatment of allergic rhinitis for pediatric

Conditions
Perennial Allergic Rhinitis
Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Registration Number
EUCTR2014-004871-22-Outside-EU/EEA
Lead Sponsor
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
A
Sex
All
Target Recruitment
87
Inclusion Criteria

Be = 1 y.o. and 15 y.o. = of age on the day of signing informed consent.
Weight: =8 kg
Is Male or Female.
Be ambulant patient
Is diagnosed as PAR and has symptom of PAR at Visit 1.
Has allergic rhinitis type classified into Nasal blocked type” or combined type” at Visit 2

Are the trial subjects under 18? yes
Number of subjects for this age range: 87
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Is diagnosed as either acute rhinitis*, simple rhinitis, rhinitis Congestive, rhinitis atrophic, Sinusitis with Purulent nasal discharge, Rhinitis medicamentosa, or nonallergic rhinitis (e.g., Vasomotor rhinitis, Eosinophilic rhinitis). *The subject develops acute nasal infections such as acute rhinitis cannot be registered at Visit 2.
Has started hyposensitization therapy or non- specific immunotherapy within 6 month prior to Visit 1 and ongoing.
Has a medical history of inferior concha mucosal resection, submucous resection of inferior Tubinates or other surgery aimed to redaction and/or modulation of nasal mucosa (including electrocoagulation, cryoextraction or application of trichloroacetic acid).
Has a past or present medical history of asthma.
Has total bilirubin = 3.0mg/dl, or AST or ALT = 2.5 X ULN for the institution within 14 days prior to Visit 2.
Treated with other clinical study drug within 3 months prior to Visit1.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath